… are potentially superior therapeutic agents for metabolic disease. These include dual
agonists of PPAR-α and PPAR-γ, which beneficially alter carbohydrate and lipid metabolism in a …

… In this review we evaluate the metabolic phenotypes of … this has on controlling lipid
metabolism, glucose homeostasis, and … -targeted therapeutics to treat chronic metabolic diseases. …

… Therefore, PPARδ represents a novel therapeutic target and the development of PPARδ
gonists/modulators may be useful for treating the whole spectrum of metabolic syndrome. …

… for selective therapeutic interventions. Anti-angiogenic agents can affect adipose metabolism
and … may be used for the treatment of metabolic diseases regardless of obesity. In addition, …

… some of these metabolic disturbances. In … metabolic disorders in obese mice. We therefore
propose that MANF might be a promising target for treating chronic metabolic diseases. …

… an exciting opportunity for therapeutic interference of obesity and metabolic disease. In fact,
… body weights and metabolic rates of the host, implying a possible new therapeutic option for …

… in turn influences host metabolism and disease phenotypes. Further … therapeutic target for
a range of metabolic disorders. … an early diagnostic marker and a therapeutic target for T2DM. …

… skeletal muscle produces changes that resemble the effects of exercise training [61], making
it a potential candidate for mimicking the effects of exercise to treat metabolic diseases [62]. …

… the structural characteristics of human NPY receptors and their role in metabolic diseases. …
receptor represents an important diagnostic and therapeutic target for these types of cancer […

… metabolic diseases and pathological consequences, including diabetes, obesity, fatty liver
diseases… of proteins and pathways involved in metabolic diseases by focusing on PTM-based …